Tiziana Life Sciences Ltd
TLSA
$2.03
-$0.10-4.70%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 51.18% | 51.18% | 48.54% | 48.54% | -27.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.17% | 41.17% | -0.05% | -0.05% | -25.14% |
| Operating Income | -41.17% | -41.17% | 0.05% | 0.05% | 25.14% |
| Income Before Tax | 29.42% | 29.42% | -1.63% | -1.63% | 7.39% |
| Income Tax Expenses | -- | -- | -446.77% | -446.77% | -- |
| Earnings from Continuing Operations | -21.01% | -21.01% | 20.55% | 20.55% | 45.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.01% | -21.01% | 20.55% | 20.55% | 45.99% |
| EBIT | -41.17% | -41.17% | 0.05% | 0.05% | 25.14% |
| EBITDA | -41.27% | -41.27% | 0.06% | 0.06% | 25.20% |
| EPS Basic | -6.64% | -6.64% | 26.02% | 26.02% | 46.32% |
| Normalized Basic EPS | -19.59% | -19.59% | 2.02% | 2.02% | 27.07% |
| EPS Diluted | -6.64% | -6.64% | 26.02% | 26.02% | 46.32% |
| Normalized Diluted EPS | -19.59% | -19.59% | 2.02% | 2.02% | 27.07% |
| Average Basic Shares Outstanding | 13.32% | 13.32% | 7.38% | 7.38% | 0.81% |
| Average Diluted Shares Outstanding | 13.32% | 13.32% | 7.38% | 7.38% | 0.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |